{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:11:05Z","timestamp":1792390265879,"version":"4.4.0"},"reference-count":199,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["EEQ\/2019\/000027"],"award-info":[{"award-number":["EEQ\/2019\/000027"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.bbcan.2023.189020","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T05:13:36Z","timestamp":1699593216000},"page":"189020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives"],"prefix":"10.1016","volume":"1878","author":[{"given":"Rajesh N.","family":"Gacche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12272-020-01287-2","article-title":"Pathological angiogenesis and inflammation in tissues","volume":"44","author":"Jeong","year":"2021","journal-title":"Arch. Pharm. Res."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.133.2.275","article-title":"Isolation of a tumor factor responsible for angiogenesis","volume":"133","author":"Folkman","year":"1971","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0015","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","article-title":"Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells","volume":"161","author":"Ferrara","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6423","key":"10.1016\/j.bbcan.2023.189020_bb0020","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","article-title":"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo","volume":"362","author":"Kim","year":"1993","journal-title":"Nature."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189020_bb0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189020_bb0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189020_bb0035","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell."},{"key":"10.1016\/j.bbcan.2023.189020_bb0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.drup.2018.01.002","article-title":"Redundant angiogenic signaling and tumor drug resistance","volume":"36","author":"Gacche","year":"2018","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0045","first-page":"161","article-title":"Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy","volume":"1846","author":"Gacche","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.bbcan.2023.189020_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2015.14","article-title":"Compensatory angiogenesis and tumor refractoriness","volume":"4","author":"Gacche","year":"2015","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bbcan.2023.189020_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100849","article-title":"New insights into antiangiogenic therapy resistance in cancer: mechanisms and therapeutic aspects","volume":"64","author":"Huang","year":"2022","journal-title":"Drug Resist. Updat."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189020_bb0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41569-021-00517-4","article-title":"The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy","volume":"18","author":"Ricard","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/mef2.33","article-title":"Antiangiogenic therapy for ocular diseases: current status and challenges","volume":"2","author":"Chen","year":"2023","journal-title":"Medicine MedComm-Future."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189020_bb0070","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3892\/mmr.2021.11899","article-title":"Antiangiogenic therapy in diabetic nephropathy: a double-edged sword (review)","volume":"23","author":"Tao","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189020_bb0075","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2023.189020_bb0080","doi-asserted-by":"crossref","first-page":"1198972","DOI":"10.3389\/fimmu.2023.1198972","article-title":"The application and research progress of anti-angiogenesis therapy in tumor immunotherapy","volume":"14","author":"Tu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0090","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1002\/onco.13551","article-title":"FDA approval summary: Olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer","volume":"26","author":"Arora","year":"2021","journal-title":"Oncologist."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189020_bb0095","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","article-title":"FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.bbcan.2023.189020_bb0100","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMe2004851","article-title":"Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer","volume":"382","author":"Kelley","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189020_bb0105","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/fon-2019-0042","article-title":"Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer","volume":"16","author":"Haunschild","year":"2020","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189020_bb0110","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2020.06.021","article-title":"Atezolizumab plus bevacizumab versus Sunitinib for patients with untreated metastatic renal cell carcinoma and Sarcomatoid features: a Prespecified subgroup analysis of the IMmotion151 clinical trial","volume":"79","author":"Rini","year":"2021","journal-title":"Eur. Urol."},{"issue":"31","key":"10.1016\/j.bbcan.2023.189020_bb0115","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026862","article-title":"Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: a systematic review and meta-analysis","volume":"100","author":"Kong","year":"2021","journal-title":"Medicine (Baltimore)."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2020.11.020","article-title":"Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study","volume":"151","author":"Yamamoto","year":"2021","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","article-title":"Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy","volume":"12","author":"Qin","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189020_bb0135","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in Cancer: breakthrough and challenges of targeted therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0140","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14728214.2017.1336538","article-title":"Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma","volume":"22","author":"de Rosamel","year":"2017","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CCO.0000000000000696","article-title":"Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer","volume":"33","author":"Gong","year":"2021","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0155","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920907504","article-title":"Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma","volume":"12","author":"Rassy","year":"2020","journal-title":"Ther Adv Med Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0160","doi-asserted-by":"crossref","first-page":"567","DOI":"10.21873\/anticanres.14809","article-title":"Antiangiogenic tyrosine kinase inhibitors in metastatic colorectal cancer: focusing on regorafenib","volume":"41","author":"Papadimitriou","year":"2021","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0165","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.pbiomolbio.2013.10.001","article-title":"Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth","volume":"113","author":"Gacche","year":"2013","journal-title":"Prog. Biophys. Mol. Biol."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189020_bb0170","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut."},{"key":"10.1016\/j.bbcan.2023.189020_bb0175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40164-018-0113-x","article-title":"Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma","volume":"7","author":"Poddubskaya","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"issue":"1 Pt 1","key":"10.1016\/j.bbcan.2023.189020_bb0180","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jfma.2020.04.021","article-title":"Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan","volume":"120","author":"Lin","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189020_bb0185","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/j.clgc.2019.11.006","article-title":"Sunitinib Rechallenge in patients with metastatic renal cell carcinoma","volume":"18","author":"Nachbargauer","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2023.189020_bb0190","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1097\/MJT.0000000000001205","article-title":"Sunitinib as successful maintenance therapy for recurrent pancreatic serous cystadenocarcinoma","volume":"28","author":"Inayat","year":"2020","journal-title":"Am. J. Ther."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189020_bb0195","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/1078155220924075","article-title":"Pazopanib for metastatic soft-tissue sarcoma: a multicenter retrospective study","volume":"27","author":"Koca","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189020_bb0200","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ijc.33238","article-title":"First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: final results of the FLIPPER trial","volume":"148","author":"Staehler","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2023.189020_bb0205","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13014-020-01742-w","article-title":"Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial","volume":"16","author":"Yang","year":"2021","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2020.12.009","article-title":"Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial","volume":"145","author":"Atkins","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"18","key":"10.1016\/j.bbcan.2023.189020_bb0220","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus Nivolumab in patients with advanced gastric or colorectal Cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0225","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/neuonc\/noaa156","article-title":"A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib","volume":"23","author":"Santangelo","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101993","article-title":"Evolving role of regorafenib for the treatment of advanced cancers","volume":"86","author":"Grothey","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2023.189020_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102221","article-title":"Cabozantinib: an evolving therapy for hepatocellular carcinoma","volume":"98","author":"El-Khoueiry","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189020_bb0240","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/CCO.0000000000000644","article-title":"Cabozantinib as an emerging treatment for sarcoma","volume":"32","author":"Sch\u00f6ffski","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0245","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2020.09.030","article-title":"Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL early access program","volume":"142","author":"Albiges","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188391","article-title":"Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy","volume":"1874","author":"Zhao","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0255","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1634\/theoncologist.2019-0407","article-title":"Lenvatinib in management of solid tumors","volume":"25","author":"Hao","year":"2020","journal-title":"Oncologist."},{"issue":"11","key":"10.1016\/j.bbcan.2023.189020_bb0260","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors [published correction appears in J Clin Oncol. 2020 Aug 10;38(23):2702]","volume":"38","author":"Taylor","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0265","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000696","article-title":"Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial","volume":"8","author":"Liu","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2023.189020_bb0270","first-page":"1003","article-title":"Camrelizumab in combination with Apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label","volume":"27","author":"Xu","year":"2021","journal-title":"Phase II Trial. Clin Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0275","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3892\/ol.2020.11685","article-title":"Anlotinib as a molecular targeted therapy for tumors","volume":"20","author":"Gao","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbcan.2023.189020_bb0280","article-title":"Anlotinib: a novel targeted drug for bone and soft tissue sarcoma","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189020_bb0285","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/onco.13530","article-title":"Targeted therapy with Anlotinib for a patient with an oncogenic FGFR3-TACC3 fusion and recurrent glioblastoma","volume":"26","author":"Wang","year":"2021","journal-title":"Oncologist."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189020_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247494","article-title":"Anlotinib-containing regimen for advanced small-cell lung cancer: a protocol of meta-analysis","volume":"16","author":"Yu","year":"2021","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.bbcan.2023.189020_bb0295","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/17512433.2019.1630272","article-title":"The clinical application of fruquintinib on colorectal cancer","volume":"12","author":"Chen","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0300","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1186\/s12885-020-07486-w","article-title":"Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China","volume":"20","author":"Peng","year":"2020","journal-title":"BMC Cancer"},{"issue":"24","key":"10.1016\/j.bbcan.2023.189020_bb0305","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of Fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal Cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA."},{"issue":"24","key":"10.1016\/j.bbcan.2023.189020_bb0310","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.2217\/fon-2021-0202","article-title":"FRESCO-2: a global phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer","volume":"17","author":"Dasari","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0315","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.lungcan.2020.06.016","article-title":"A phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - the FALUCA study","volume":"146","author":"Lu","year":"2020","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0320","doi-asserted-by":"crossref","first-page":"839","DOI":"10.21037\/tlcr-20-1028","article-title":"Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study","volume":"10","author":"Lu","year":"2021","journal-title":"Transl Lung Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189020_bb0325","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/db09-0119","article-title":"Abnormal angiogenesis in diabetic nephropathy","volume":"58","author":"Nakagawa","year":"2009","journal-title":"Diabetes."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189020_bb0330","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.cell.2015.05.002","article-title":"Highly parallel genome-wide expression profiling of individual cells using Nanoliter droplets","volume":"161","author":"Macosko","year":"2015","journal-title":"Cell."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0335","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","article-title":"The role of vascular endothelial growth factor in ocular health and disease","volume":"25","author":"Adamis","year":"2005","journal-title":"Retina."},{"issue":"6382","key":"10.1016\/j.bbcan.2023.189020_bb0340","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0345","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41419-017-0061-0","article-title":"Defining the role of the tumor vasculature in antitumor immunity and immunotherapy","volume":"9","author":"Schaaf","year":"2018","journal-title":"Cell Death Dis."},{"issue":"18","key":"10.1016\/j.bbcan.2023.189020_bb0350","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2023.189020_bb0355","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0360","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3390\/jcm11020378","article-title":"Therapeutic advances in diabetic nephropathy","volume":"11","author":"Sawaf","year":"2022","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0365","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s004280000311","article-title":"On glomerular structural alterations in type-1 diabetes. Companions of early diabetic glomerulopathy","volume":"438","author":"Osterby","year":"2001","journal-title":"Virchows Arch."},{"issue":"9","key":"10.1016\/j.bbcan.2023.189020_bb0370","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/sj.ki.5000294","article-title":"Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man","volume":"69","author":"Hohenstein","year":"2006","journal-title":"Kidney Int."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189020_bb0375","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41581-021-00411-9","article-title":"Phenotypic diversity and metabolic specialization of renal endothelial cells","volume":"17","author":"Dumas","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189020_bb0380","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41581-020-0260-2","article-title":"Targeting angiogenesis and lymphangiogenesis in kidney disease","volume":"16","author":"Tanabe","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189020_bb0385","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/HYPERTENSIONAHA.116.08319","article-title":"Small vessels, big role: renal microcirculation and progression of renal injury","volume":"69","author":"Chade","year":"2017","journal-title":"Hypertension."},{"key":"10.1016\/j.bbcan.2023.189020_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.862545","article-title":"Increased serum VEGF-B level is associated with renal function impairment in patients with type 2 diabetes","volume":"13","author":"Wei","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.bbcan.2023.189020_bb0395","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fbioe.2018.00007","article-title":"Biology of vascular endothelial growth factor C in the morphogenesis of lymphatic vessels","volume":"6","author":"Rauniyar","year":"2018","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189020_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096932","article-title":"Urinary and plasma levels of vasohibin-1 can predict renal functional deterioration in patients with renal disorders","volume":"9","author":"Hinamoto","year":"2014","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.bbcan.2023.189020_bb0405","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1681\/ASN.2006101093","article-title":"Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia","volume":"18","author":"Davis","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189020_bb0410","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1681\/ASN.2018060599","article-title":"LRG1 promotes diabetic kidney disease progression by enhancing TGF-\u03b2-induced angiogenesis","volume":"30","author":"Hong","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189020_bb0415","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrneph.2013.35","article-title":"Angiogenesis and hypoxia in the kidney","volume":"9","author":"Tanaka","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0420","doi-asserted-by":"crossref","first-page":"5724069","DOI":"10.1155\/2017\/5724069","article-title":"Antiangiogenic therapy for diabetic nephropathy","volume":"2017","author":"Tanabe","year":"2017","journal-title":"Biomed. Res. Int."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0425","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/j.ajkd.2004.09.020","article-title":"Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy","volume":"45","author":"Kanesaki","year":"2005","journal-title":"Am. J. Kidney Dis."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0430","doi-asserted-by":"crossref","first-page":"F399","DOI":"10.1152\/ajprenal.00617.2018","article-title":"Herniation of the tuft with outgrowth of vessels through the glomerular entrance in diabetic nephropathy damages the juxtaglomerular apparatus","volume":"317","author":"L\u00f6wen","year":"2019","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0435","article-title":"Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab","volume":"8","author":"Hanna","year":"2020","journal-title":"SAGE Open Med Case Rep."},{"key":"10.1016\/j.bbcan.2023.189020_bb0440","article-title":"Glomerular endothelial cells are the coordinator in the development of diabetic nephropathy","volume":"8","author":"Li","year":"2021","journal-title":"Front Med (Lausanne)."},{"issue":"11","key":"10.1016\/j.bbcan.2023.189020_bb0445","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/diabetes.48.11.2229","article-title":"Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes","volume":"48","author":"Cooper","year":"1999","journal-title":"Diabetes."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189020_bb0450","first-page":"529","article-title":"Serum and plasma levels of vascular endothelial growth factors in relation to quality of glucose control, biomarkers of inflammation, and diabetic nephropathy [published correction appears in Horm Metab res. 2016 Sep;48(9):620]","volume":"48","author":"Hanefeld","year":"2016","journal-title":"Horm. Metab. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0455","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1523-1755.2005.00067.x","article-title":"Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy","volume":"67","author":"Kim","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.bbcan.2023.189020_bb0460","doi-asserted-by":"crossref","first-page":"1925424","DOI":"10.1155\/2016\/1925424","article-title":"Levels of serum 25(OH)VD3, HIF-1\u03b1, VEGF, vWf, and IGF-1 and their correlation in type 2 diabetes patients with different urine albumin creatinine ratio","volume":"2016","author":"Shao","year":"2016","journal-title":"J. Diabetes Res."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189020_bb0465","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028804","article-title":"Serum VEGF-D level is correlated with renal dysfunction and proteinuria in patients with diabetic chronic kidney disease","volume":"101","author":"Nguyen","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"10.1016\/j.bbcan.2023.189020_bb0470","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.ki.5002101","article-title":"Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss","volume":"71","author":"Baelde","year":"2007","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189020_bb0475","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.ajkd.2003.12.028","article-title":"Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy","volume":"43","author":"Baelde","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.bbcan.2023.189020_bb0480","article-title":"Mechanistic pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy","volume":"13","author":"Yang","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.bbcan.2023.189020_bb0485","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/184539","article-title":"Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy","volume":"2013","author":"Nakagawa","year":"2013","journal-title":"J. Diabetes Res."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0490","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000365156","article-title":"Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials","volume":"40","author":"Lafayette","year":"2014","journal-title":"Am. J. Nephrol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116527","article-title":"Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer","volume":"10","author":"Feliu","year":"2015","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.bbcan.2023.189020_bb0500","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2023.189020_bb0505","first-page":"2919080","article-title":"Intravitreal injection of anti-VEGF antibody induces glomerular endothelial cells injury","volume":"2019","author":"Touzani","year":"2019","journal-title":"Case Rep Nephrol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0510","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ckj\/sfy060","article-title":"Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension","volume":"12","author":"Hanna","year":"2019","journal-title":"Clin. Kidney J."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189020_bb0515","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/br.2022.1529","article-title":"Early biomarkers of nephrotoxicity associated with the use of anti-VEGF drugs","volume":"16","author":"Chebotareva","year":"2022","journal-title":"Biomed Rep."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189020_bb0520","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189020_bb0525","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","article-title":"Bevacizumab-associated glomerular microangiopathy","volume":"32","author":"Person","year":"2019","journal-title":"Mod. Pathol."},{"issue":"12","key":"10.1016\/j.bbcan.2023.189020_bb0530","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/ki.2011.288","article-title":"Proteinuria and hypertension with tyrosine kinase inhibitors","volume":"80","author":"Kandula","year":"2011","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0535","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated Nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0540","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-physiol-020518-114700","article-title":"Normalizing function of tumor vessels: Progress, opportunities, and challenges","volume":"81","author":"Martin","year":"2019","journal-title":"Annu. Rev. Physiol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0545","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/08820538.2022.2152706","article-title":"Molecular mediators and regulators of retinal angiogenesis","volume":"38","author":"Vishwakarma","year":"2023","journal-title":"Semin. Ophthalmol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0550","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","article-title":"Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration","volume":"21","author":"Khachigian","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2023.189020_bb0555","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2147\/DDDT.S383101","article-title":"Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis","volume":"16","author":"Xu","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bbcan.2023.189020_bb0560","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40942-018-0143-x","article-title":"Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding","volume":"4","author":"de Lima","year":"2018","journal-title":"Int J Retina Vitreous."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0565","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41433-022-02020-7","article-title":"Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis","volume":"37","author":"Rosenberg","year":"2023","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.bbcan.2023.189020_bb0570","article-title":"Sovremennye tendentsii anti-VEGF -terapii vozrastnoi makulyarnoi degeneratsii [modern trends in anti-VEGF therapy for age-related macular degeneration]","volume":"139(3. Vyp. 2):46-50","author":"Budzinskaya","year":"2023","journal-title":"Vestn. Oftalmol."},{"issue":"27","key":"10.1016\/j.bbcan.2023.189020_bb0575","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.bbcan.2023.189020_bb0580","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0585","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12886-023-02780-0","article-title":"Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis","volume":"23","author":"Tsai","year":"2023","journal-title":"BMC Ophthalmol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0590","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001104","article-title":"Ranibizumab port delivery system: a clinical perspective","volume":"7","author":"Eichenbaum","year":"2022","journal-title":"BMJ Open Ophthalmol."},{"issue":"11","key":"10.1016\/j.bbcan.2023.189020_bb0595","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/biom12111629","article-title":"Current and novel therapeutic approaches for treatment of Neovascular age-related macular degeneration","volume":"12","author":"ElSheikh","year":"2022","journal-title":"Biomolecules."},{"key":"10.1016\/j.bbcan.2023.189020_bb0600","article-title":"KSI-301: antibody biopolymer conjugate in retinal disorders","volume":"13","author":"Chandrasekaran","year":"2021","journal-title":"Ther Adv Ophthalmol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0605","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of Brolucizumab for Neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology."},{"issue":"12","key":"10.1016\/j.bbcan.2023.189020_bb0610","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration [published correction appears in ophthalmology. 2013 Jan;120(1):209-10]","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189020_bb0615","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/s41433-022-02092-5","article-title":"Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies [published correction appears in Eye (Lond). 2022 Jun 8;:]","volume":"37","author":"Lally","year":"2023","journal-title":"Eye (Lond)."},{"issue":"10326","key":"10.1016\/j.bbcan.2023.189020_bb0620","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet."},{"issue":"10326","key":"10.1016\/j.bbcan.2023.189020_bb0625","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189020_bb0630","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10384-023-00985-w","volume":"67","author":"Mori","year":"2023","journal-title":"Jpn. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189020_bb0635","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000526044","article-title":"Intravitreal Aflibercept versus Brolucizumab for treatment-naive Neovascular age-related macular degeneration with type 1 macular neovascularization: comparison of short-term outcomes","volume":"245","author":"Hoshino","year":"2022","journal-title":"Ophthalmologica."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189020_bb0640","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/imm.13008","article-title":"A Nobel prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens","volume":"155","author":"Altmann","year":"2018","journal-title":"Immunology."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0645","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/clinpract13010003","article-title":"The role of immune checkpoint inhibitors in Cancer therapy","volume":"13","author":"Basudan","year":"2022","journal-title":"Clin Pract."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189020_bb0650","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0655","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/25785826.2021.1976942","article-title":"Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy","volume":"45","author":"Kubo","year":"2022","journal-title":"Immunol Med."},{"key":"10.1016\/j.bbcan.2023.189020_bb0660","doi-asserted-by":"crossref","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0665","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2023.189020_bb0670","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/exd.14716","article-title":"Resistance to immune checkpoint inhibitors and the tumor microenvironment","volume":"32","author":"Kawashima","year":"2023","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216182","article-title":"Immune-checkpoint inhibitor resistance in cancer treatment: current progress and future directions","volume":"562","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189020_bb0680","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0685","doi-asserted-by":"crossref","first-page":"1198972","DOI":"10.3389\/fimmu.2023.1198972","article-title":"The application and research progress of anti-angiogenesis therapy in tumor immunotherapy","volume":"14","author":"Tu","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189020_bb0690","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.bbcan.2023.189020_bb0695","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159839","article-title":"Hypoxia-inducible factors: cancer progression and clinical translation","volume":"132","author":"Wicks","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0700","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis."},{"issue":"9","key":"10.1016\/j.bbcan.2023.189020_bb0705","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tips.2019.07.001","article-title":"Tumor vasculatures: a new target for Cancer immunotherapy","volume":"40","author":"Liu","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0710","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2023.189020_bb0715","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.bbcan.2023.189020_bb0720","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells [published correction appears in Nat Med 1996 Nov;2(11):1267]","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189020_bb0725","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/jcmm.17666","article-title":"Transforming growth factor-\u03b2 signalling in tumour resistance to the anti-PD-(L)1 therapy: updated","volume":"27","author":"Mortezaee","year":"2023","journal-title":"J. Cell. Mol. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2023.189020_bb0730","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.3390\/ijms20122970","article-title":"Multifaceted role of the placental growth factor (PlGF) in the antitumor immune response and Cancer progression","volume":"20","author":"Albonici","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2023.189020_bb0735","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for Cancer treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189020_bb0740","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"Pt 3","key":"10.1016\/j.bbcan.2023.189020_bb0745","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.semcancer.2022.02.009","article-title":"Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity","volume":"86","author":"Anderson","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0750","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12964-022-00838-y","article-title":"Cancer combination therapies by angiogenesis inhibitors; a comprehensive review","volume":"20","author":"Ansari","year":"2022","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bbcan.2023.189020_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154241","article-title":"Recent progress in cancer immunotherapy: overview of current status and challenges","volume":"241","author":"Darvishi","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"9","key":"10.1016\/j.bbcan.2023.189020_bb0760","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cac2.12183","article-title":"Improving antitumor immunity using antiangiogenic agents: mechanistic insights, current progress, and clinical challenges","volume":"41","author":"Li","year":"2021","journal-title":"Cancer Commun (Lond)."},{"key":"10.1016\/j.bbcan.2023.189020_bb0765","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.964779","article-title":"Efficacy and safety of immune checkpoint inhibitors-combined antiangiogenic drugs in the treatment of hepatocellular carcinoma: a systematic review and meta analysis","volume":"12","author":"Zhong","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0770","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00262-022-03251-z","article-title":"Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients","volume":"72","author":"Feng","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"44","key":"10.1016\/j.bbcan.2023.189020_bb0775","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031479","article-title":"Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: a meta-analysis","volume":"101","author":"Xian","year":"2022","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.bbcan.2023.189020_bb0780","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.670313","article-title":"Combination of immune checkpoint inhibitors and anti-Angiogenic agents in brain metastases from non-small cell lung Cancer","volume":"11","author":"Fang","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0785","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12890-023-02470-z","article-title":"Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study","volume":"23","author":"Ma","year":"2023","journal-title":"BMC Pulm. Med."},{"issue":"24","key":"10.1016\/j.bbcan.2023.189020_bb0790","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189020_bb0795","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/cancers15041048","article-title":"Combinations of anti-Angiogenic agents and immune checkpoint inhibitors in renal cell carcinoma: best option?","volume":"15","author":"Granet-Vaissiere","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"22","key":"10.1016\/j.bbcan.2023.189020_bb0800","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189020_bb0805","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0810","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.812916","article-title":"Interactions between anti-Angiogenic therapy and immunotherapy in glioblastoma","volume":"11","author":"Jain","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189020_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100559","article-title":"MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer","volume":"7","author":"Tabernero","year":"2022","journal-title":"ESMO Open."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189020_bb0820","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ijc.34332","article-title":"Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: a pharmacovigilance analysis","volume":"152","author":"Gu","year":"2023","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2023.189020_bb0825","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma [published correction appears in Nat Med. 2018 Dec;24(12):1941]","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189020_bb0830","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0835","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s10637-023-01349-4","article-title":"Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan red cross liver study group","volume":"41","author":"Takaki","year":"2023","journal-title":"Invest. New Drugs"},{"issue":"1\u20132","key":"10.1016\/j.bbcan.2023.189020_bb0840","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.drup.2009.12.001","article-title":"Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy","volume":"13","author":"Abdollahi","year":"2010","journal-title":"Drug Resist. Updat."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189020_bb0845","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bbcan.2023.189020_bb0850","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/path.4052","article-title":"Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors","volume":"227","author":"Chung","year":"2012","journal-title":"J. Pathol."},{"issue":"9","key":"10.1016\/j.bbcan.2023.189020_bb0855","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat. Med."},{"issue":"20","key":"10.1016\/j.bbcan.2023.189020_bb0860","doi-asserted-by":"crossref","first-page":"E1214","DOI":"10.1073\/pnas.1203794109","article-title":"Normalization of the tumor vasculature through oncogenic inhibition: an emerging paradigm in tumor biology","volume":"109","author":"Goel","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189020_bb0865","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1919764117","article-title":"Combining microenvironment normalization strategies to improve cancer immunotherapy","volume":"117","author":"Mpekris","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6453","key":"10.1016\/j.bbcan.2023.189020_bb0870","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1126\/science.aaw7875","article-title":"Vascular regulation of antitumor immunity","volume":"365","author":"Munn","year":"2019","journal-title":"Science."},{"issue":"46","key":"10.1016\/j.bbcan.2023.189020_bb0875","doi-asserted-by":"crossref","first-page":"14325","DOI":"10.1073\/pnas.1518808112","article-title":"Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients","volume":"112","author":"Tolaney","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0880","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41698-021-00197-w","article-title":"Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients","volume":"5","author":"Boucher","year":"2021","journal-title":"NPJ Precis Oncol."},{"issue":"43","key":"10.1016\/j.bbcan.2023.189020_bb0885","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189020_bb0890","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death Receptor-1 and vascular endothelial growth factor Receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology."},{"issue":"9","key":"10.1016\/j.bbcan.2023.189020_bb0895","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/jnci\/djac051","article-title":"Increased CD8+ T-cell infiltration and efficacy for multikinase inhibitors after PD-1 blockade in hepatocellular carcinoma","volume":"114","author":"Kikuchi","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"issue":"7649","key":"10.1016\/j.bbcan.2023.189020_bb0900","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189020_bb0905","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268244","article-title":"Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models","volume":"17","author":"Li","year":"2022","journal-title":"PloS One"},{"key":"10.1016\/j.bbcan.2023.189020_bb0910","doi-asserted-by":"crossref","first-page":"5867047","DOI":"10.1155\/2023\/5867047","article-title":"Vascular normalization was associated with colorectal tumor regression upon anti-PD-L1 combinational therapy","volume":"2023","author":"Zhang","year":"2023","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.bbcan.2023.189020_bb0915","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2022.03.008","article-title":"Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy","volume":"345","author":"Mpekris","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2023.189020_bb0920","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3389\/fimmu.2018.03107","article-title":"Combining radiotherapy with anti-angiogenic therapy and immunotherapy; a therapeutic triad for cancer?","volume":"9","author":"Goedegebuure","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0925","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in Cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189020_bb0930","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0935","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"Pt 2","key":"10.1016\/j.bbcan.2023.189020_bb0940","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.semcancer.2022.03.001","article-title":"Nano-targeting vascular remodeling in cancer: recent developments and future directions","volume":"86","author":"Giordo","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2023.189020_bb0945","article-title":"The research Progress of antiangiogenic therapy, immune therapy and tumor microenvironment","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189020_bb0950","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0955","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2023.189020_bb0960","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005413","article-title":"Maximizing the value of phase III trials in immuno-oncology: a checklist from the Society for Immunotherapy of Cancer (SITC)","volume":"10","author":"Atkins","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2023.189020_bb0965","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189020_bb0970","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1601","article-title":"Gene correction of the CLN3 c.175G>A variant in patient-derived induced pluripotent stem cells prevents pathological changes in retinal organoids","volume":"9","author":"Zhang","year":"2021","journal-title":"Mol Genet Genomic Med."},{"key":"10.1016\/j.bbcan.2023.189020_bb0975","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2020.594984","article-title":"CRISPR Technology for Ocular Angiogenesis","volume":"2","author":"Chung","year":"2020","journal-title":"Front Genome Ed."},{"key":"10.1016\/j.bbcan.2023.189020_bb0980","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.omtm.2020.01.006","article-title":"Factors impacting efficacy of AAV-mediated CRISPR-based genome editing for treatment of choroidal neovascularization","volume":"17","author":"Chung","year":"2020","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"19","key":"10.1016\/j.bbcan.2023.189020_bb0985","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.3390\/ijms20194876","article-title":"Adult stem cell therapeutics in diabetic retinopathy","volume":"20","author":"Gaddam","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189020_bb0990","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s13287-022-03073-x","article-title":"Advances in cell therapies using stem cells\/progenitors as a novel approach for neurovascular repair of the diabetic retina","volume":"13","author":"Lechner","year":"2022","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"10.1016\/j.bbcan.2023.189020_bb0995","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3727\/096368915X688263","article-title":"Retinal angiogenesis effects of TGF-\u03b21 and paracrine factors secreted from human placental stem cells in response to a pathological environment","volume":"25","author":"Kim","year":"2016","journal-title":"Cell Transplant."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X23001695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X23001695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T19:59:12Z","timestamp":1730491152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X23001695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":199,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0304419X23001695"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2023.189020","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2023.189020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"189020"}}